Company intelligence / Profile preview
Amorphical
- Ownership
- Private
- Employees
- ~17
- Development stage
- Phase 2
Overview
Clinical and preclinical trials have demonstrated that ACC has at least twice better absorption than crystalline calcium carbonate and significantly better than calcium citrate. ACC has shown anti-cancer properties and effectiveness in managing COVID-19 in clinical studies.
- Therapeutic areas
- RheumatologyEndocrinologyImmunologyOncologyNeurologyInfectious Diseases
- Modalities
- Amorphous nano-mineralsspecifically Amorphous Calcium Carbonate (ACC)
- Industry
- Biotech
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Amorphical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Amorphical.